- Home
- CRDL vs SVII Comparison
CRDL vs SVII Comparison
Compare CRDL & SVII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- SVII
- Stock Information
- Founded
- CRDL 2017
- SVII 2021
- Country
- CRDL Canada
- SVII United States
- Employees
- CRDL N/A
- SVII N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- SVII Blank Checks
- Sector
- CRDL Health Care
- SVII Finance
- Exchange
- CRDL Nasdaq
- SVII Nasdaq
- Market Cap
- CRDL 104.5M
- SVII 111.1M
- IPO Year
- CRDL N/A
- SVII 2022
- Fundamental
- Price
- CRDL $1.23
- SVII $11.28
- Analyst Decision
- CRDL Strong Buy
- SVII
- Analyst Count
- CRDL 3
- SVII 0
- Target Price
- CRDL $9.00
- SVII N/A
- AVG Volume (30 Days)
- CRDL 298.3K
- SVII 7.2K
- Earning Date
- CRDL 11-14-2024
- SVII 01-01-0001
- Dividend Yield
- CRDL N/A
- SVII N/A
- EPS Growth
- CRDL N/A
- SVII 13.16
- EPS
- CRDL N/A
- SVII 0.36
- Revenue
- CRDL N/A
- SVII N/A
- Revenue This Year
- CRDL N/A
- SVII N/A
- Revenue Next Year
- CRDL N/A
- SVII N/A
- P/E Ratio
- CRDL N/A
- SVII $31.25
- Revenue Growth
- CRDL N/A
- SVII N/A
- 52 Week Low
- CRDL $0.96
- SVII $10.87
- 52 Week High
- CRDL $3.12
- SVII $11.70
- Technical
- Relative Strength Index (RSI)
- CRDL 35.88
- SVII 63.22
- Support Level
- CRDL $1.17
- SVII $11.20
- Resistance Level
- CRDL $1.30
- SVII $11.24
- Average True Range (ATR)
- CRDL 0.08
- SVII 0.00
- MACD
- CRDL 0.00
- SVII 0.00
- Stochastic Oscillator
- CRDL 17.65
- SVII 100.00
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.